^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    FAT2 mutation

    i
    Other names: FAT2, FAT Atypical Cadherin 2, MEGF1, CDHF8, HFAT2, CDHR9, Multiple Epidermal Growth Factor-Like Domains Protein 1, Multiple EGF-Like Domains Protein 1, Cadherin-Related Family Member 9, Cadherin Family Member 8, Protocadherin Fat 2, Multiple Epidermal Growth Factor-Like Domains 1, FAT Tumor Suppressor (Drosophila) Homolog 2, FAT Tumor Suppressor Homolog 2 (Drosophila), FAT Tumor Suppressor Homolog 2, Protocadherin FAT2, KIAA0811, SCA45, HFat2
    Entrez ID:
    2196
    1year
    FAT2 mutation is associated with better prognosis and responsiveness to immunotherapy in uterine corpus endometrial carcinoma. (PubMed, Cancer Med)
    UCEC patients with FAT2 mutations have better prognosis and are more likely to respond to immunotherapy. FAT2 mutation may be a valuable predictor for prognosis and responsiveness to immunotherapy in UCEC patients.
    Journal • Tumor mutational burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • FAT2 (FAT Atypical Cadherin 2)
    |
    FAT2 mutation